Update on GMDN Governance
![](https://www.gmdnagency.org/wp-content/uploads/2023/06/The-value-of-a-globally-harmonised-nomenclature-for-medical-devices-2-1024x536.jpg)
21 March 2023
MHRA and ANVISA representatives have joined the Authorities Strategic Advisory Group (ASAG) committee, which represents medical device regulators that use the GMDN.
Earlier in 2022, the GMDN Trustees established the ASAG committee.
The ASAG’s key role is to provide advice and feedback to Trustees and the GMDN Agency, including:- Having appropriate review structures in place to ensure that relevant stakeholders, including from different regions, can provide feedback and be consulted about the GMDN supporting their needs.
- The promotion of the GMDN to encourage broader adoption and global harmonisation of the GMDN as a detailed nomenclature that underpins an efficient and effective regulatory model of safety and performance for medical devices.
- Enhancing medical device safety by use of the GMDN that facilitates and promotes data exchange and analysis.
Recent Posts
- GMDN Agency and partners receive Innovate UK funding to research post-market medical device intelligence July 22, 2024
- New Software Developer joins GMDN Agency to improve digital offering July 17, 2024
- GMDN Agency and NHS Supply Chain announce collaboration agreement July 15, 2024
- WHO and GMDN Agency sign agreement in support of global harmonisation of medical device nomenclatures July 8, 2024
- GMDN FOCUS – June 2024 June 30, 2024